Tratamiento farmacológico en la práctica clínica en el trastorno bipolar

  1. Varela Gómez, Noemí
  2. Ferrier, Nicol
Revista:
Norte de Salud Mental

ISSN: 1578-4940

Año de publicación: 2011

Volumen: 9

Número: 39

Páginas: 11-18

Tipo: Artículo

Otras publicaciones en: Norte de Salud Mental

Resumen

El trastorno bipolar es una enfermedad crónica, siendo su tratamiento adecuado esencial para disminuir recaídas y mejorar el pronóstico de este trastorno, no tan benévolo como se describió inicialmente. El objetivo es analizar el tratamiento farmacológico recibido en pacientes con trastorno bipolar en la práctica clínica.

Referencias bibliográficas

  • Bourdon KH, Rae DS, Locke BZ, Narrow WE, Regier DA. Estimating the prevalence of mental disorders in U.S. adults from the Epidemiologic Catchment Area Survey. Public Health Rep 1992 Nov-Dec;107(6):663-8.
  • Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12- month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 Jan;51(1):8-19.
  • Weissman MM, Broadhead WE, Olfson M, Sheehan DV, Hoven C, Conolly P, et al. A diagnostic aid for detecting (DSM-IV) mental disorders in primary care. Gen Hosp Psychiatry 1998 Jan;20(1):1-11.
  • Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord 2003 Jan;73(1-2):123-31.
  • Parikh SV, Wasylenki D, Goering P, Wong J. Mood disorders: rural/urban differences in prevalence, health care utilization, and disability in Ontario. J Affect Disord 1996 Apr 26;38(1):57-65.
  • Murray CJ, Lopez AD. Evidence-based health policy—lessons from the Global Burden of Disease Study. Science 1996 Nov 1;274(5288): 740-3.
  • Calabrese JR, Hirschfeld RM, Reed M, Davies MA, Frye MA, Keck PE, et al. Impact of bipolar disorder on a U.S. community sample. J Clin Psychiatry 2003 Apr;64(4):425-32.
  • Hirschfeld RM, Calabrese JR, Weissman MM, Reed M, Davies MA, Frye MA, et al. Screening for bipolar disorder in the community. J Clin Psychiatry 2003 Jan;64(1):53-9.
  • Lish JD, Dime-Meenan S, Whybrow PC, Price RA, Hirschfeld RM. The National Depressive and Manic-depressive Association (DMDA) survey of bipolar members. J Affect Disord 1994 Aug;31(4):281-94.
  • Judd LL, Schettler PJ, Akiskal HS, Maser J, Coryell W, Solomon D, et al. Long-term symptomatic status of bipolar I vs. bipolar II disorders. Int J Neuropsychopharmacol 2003 Jun; 6(2):127-37.
  • Judd LL, Schettler PJ, Akiskal HS, Coryell W, Leon AC, Maser JD, et al. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/ recurrence. Arch Gen Psychiatry 2008 Apr; 65(4):386-94.
  • Vieta E, Colom F, Martinez-Aran A, Benabarre A, Reinares M, Gasto C. Bipolar II disorder and comorbidity. Compr Psychiatry 2000 SepOct;41(5):339-43.
  • Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, Keck PE, Jr., et al. Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers. Am J Psychiatry 2006 Feb;163(2):232-9.
  • Moller HJ, Bottlender R, Grunze H, Strauss A, Wittmann J. Are antidepressants less effective in the acute treatment of bipolar I compared to unipolar depression? J Affect Disord 2001 Dec;67(1-3):141-6.
  • Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition–recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009 Jun;23(4):346-88.
  • Vieta E, Nolen WA, Grunze H, Licht RW, Goodwin G. A European perspective on the Canadian guidelines for bipolar disorder. Bipolar Disord 2005;7 Suppl 3:73-6.
  • Grunze H, Kasper S, Goodwin G, Bowden C, Moller HJ. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders, part III: maintenance treatment. World J Biol Psychiatry 2004 Jul;5(3):120-35.
  • Post RM, Leverich GS, Altshuler L, Mikalauskas K. Lithium-discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry 1992 Dec;149(12):1727-9.
  • Faedda GL, Baldessarini RJ, Tohen M, Strakowski SM, Waternaux C. Episode sequence in bipolar disorder and response to lithium treatment. Am J Psychiatry 1991 Sep; 148(9):1237-9.
  • Fountoulakis KN, Vieta E, Siamouli M, Valenti M, Magiria S, Oral T, et al. Treatment of bipolar disorder: a complex treatment for a multi-faceted disorder. Ann Gen Psychiatry 2007;6:27.
  • Yatham LN, Kennedy SH, O’Donovan C, Parikh S, MacQueen G, McIntyre R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar Disord 2005;7 Suppl 3:5-69.
  • Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005 Apr; 85(3):259-66.
  • Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987 Mar; 48(3):89-93.
  • Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980 Jul;137(7):782-90.
  • Blackburn SC, Oliart AD, Garcia Rodriguez LA, Perez Gutthann S. Antiepileptics and blood dyscrasias: a cohort study. Pharmacotherapy 1998 Nov-Dec;18(6):1277-83.
  • Grunze H, Kasper S, Goodwin G, Bowden C, Baldwin D, Licht RW, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders, Part II: Treatment of Mania. World J Biol Psychiatry 2003 Jan;4(1):5-13.
  • Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002 Feb;63(2):120-5.
  • Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004 Apr 24;363(9418):1341-5.
  • Brown EB, McElroy SL, Keck PE, Jr., Deldar A, Adams DH, Tohen M, et al. A 7-week, rando- mized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006 Jul;67(7):1025-33.
  • Post RM, Denicoff KD, Leverich GS, Altshuler LL, Frye MA, Suppes TM, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003 Jun;64(6):680-90; quiz 738-9.
  • Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002 Jun;59(6):530-7.
  • Keller MB, Lavori PW, Coryell W, Andreasen NC, Endicott J, Clayton PJ, et al. Differential outcome of pure manic, mixed/cycling, and pure depressive episodes in patients with bipolar illness. JAMA 1986 Jun 13;255(22): 3138-42.
  • Yatham LN, Lecrubier Y, Fieve RR, Davis KH, Harris SD, Krishnan AA. Quality of life in patients with bipolar I depression: data from 920 patients. Bipolar Disord 2004 Oct;6(5): 379-85
  • Calabrese JR, Shelton MD, Bowden CL, Rapport DJ, Suppes T, Shirley ER, et al. Bipolar rapid cycling: focus on depression as its hallmark. J Clin Psychiatry 2001;62 Suppl 14:34-41.